EffRx Pharmaceuticals   Report issue

For profit Phase 2
Founded: Freienbach Switzerland (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2019
NCT04403698
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

EffRx Pharmaceuticals

Active Ingredients

Drugs in Phase 2 Trials (1)

alendronic acid (fosamax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1